The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
FiberCon
Synonyms :
Polycarbophil calcium
Class :
Laxatives
Brand Name :
FiberCon
Synonyms :
Polycarbophil calcium
Class :
Laxatives
Dosage Forms & StrengthsÂ
CapletsÂ
625gÂ
caplets
Orally 
4 times a day
One caplet orally, up to four times a day
Note: not to administer more than 8 caplets a day
Do not administer this drug for more than a week
CapletsÂ
625gÂ
For children of 12 years of age and above:
One caplet orally, up to two caplets a day
Note: seek advice from the doctor to administer calcium polycarbophyl to children under 12 years of age
Refer to adult dosingÂ
calcium salts: they may diminish the absorption of quinolones
calcium salts: they may diminish the absorption of quinolones
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption of quinolones
may diminish the serum concentration of magnesium salts
may increase the adverse effect when combined
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
dolutegravir: they may diminish the serum concentration of calcium salts
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
magnesium salts: they may diminish the absorption of phosphate binders
magnesium salts: they may diminish the absorption of phosphate binders
magnesium salts: they may diminish the absorption of phosphate binders
magnesium salts: they may diminish the absorption of phosphate binders
magnesium salts: they may diminish the absorption of phosphate binders
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may diminish the serum concentration when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may increase the toxic effects of vitamin D analogs
may diminish the serum concentration of magnesium salts
estramustine: they may diminish the absorption of calcium salts
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may enhance the arrhythmogenic effect of cardiac glycosides
may enhance the arrhythmogenic effect of cardiac glycosides
may enhance the arrhythmogenic effect of cardiac glycosides
calcium salts increase the toxicity of vitamin D analogs
may increase the arrhythmogenic effect of cardiac glycosides
may increase the arrhythmogenic effect of cardiac glycosides
may increase the arrhythmogenic effect of cardiac glycosides
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
the therapeutic activity of acebutolol may be decreased
the risk of dehydration may be increased
the risk of adverse effects may be increased
the risk of dehydration can be increased
the therapeutic activity of calcium polycarbophyl may be decreased
the risk of dehydration can be increased
the therapeutic activity of calcium polycarbophyl may be decreased
the risk of dehydration can be increased
the therapeutic activity of calcium polycarbophyl may be decreased
the risk of dehydration can be increased
the risk or intensity of adverse effects can be heightened when calcipotriol is combined with calcium polycarbophil
the risk or intensity of unfavorable effects can be heightened when tacalcitol is linked with calcium polycarbophil
calcium salts reduces the efficacy of dobutamine
The therapeutic efficacy of dobutamine may be diminished when used concurrently with calcium salts
thiazide: they may enhance the serum concentration when combined with calcium salts
thiazide: they may enhance the serum concentration when combined with calcium salts
thiazide: they may enhance the serum concentration when combined with calcium salts
thiazide: they may enhance the serum concentration when combined with calcium salts
may diminish the excretion when combined with calcium salts
may diminish the excretion when combined with calcium salts
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
spironolactone and hydrochlorothiazide
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
Actions and spectrum:Â
It causes the stool to become bulkier, which facilitates bowel movement. Additionally, it functions by increasing the water content in stool, which softens and facilitates passing it.Â
Frequency not definedÂ
NauseaÂ
VomitingÂ
Sudden difference in bowel habitsÂ
Pain in the abdomenÂ
Black Box Warning Â
To be taken with excessive floating as this may block the esophagus and cause chokingÂ
Contraindication/Caution:Â
Contraindication:Â
Hypersensitivity Â
Pregnancy consideration:Â Â
USFDA pregnancy category: Limited data availableÂ
Lactation:Â Â
Limited data availableÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Calcium polycarbophyl is a bulk-forming laxativeÂ
Pharmacodynamics:Â
It is known to relieve diarrhea and constipation by regularising bowel movementsÂ
Pharmacokinetics:Â
AbsorptionÂ
It is not absorbed in the intestineÂ
DistributionÂ
MetabolismÂ
It is not metabolized and is known to have limited hydrophilic properties in an acidic environment.Â
Elimination and excretionÂ
Calcium polycarbophyl is known to be excreted in feces Â
Half life:Â
Administration:Â
Take caplets with a glass full of water (8 ounces) to avoid choking.Â
Patient information leafletÂ
Generic Name: calcium polycarbophil Â
Why do we use calcium polycarbophil?Â
Calcium polycarbophyl is a bulk-forming laxative used to treat constipation. The onset of action can be generally seen in 12 to 72 hours. It is also used in relieving diarrhea.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
